

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

*Complete if Known*

Application Number:

Filing Date

First Named Inventor

Art Unit

Examiner Name

Attorney Docket Number

AN 2004.00

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner's  
Signature

Date  
Considered

6/24/04

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2


Complete if Known

Application Number 10/021,820  
Filing Date December 13, 2001  
First Named Inventor Kin-Ping WONG  
Art Unit 1651 1619  
Examiner Name Not Yet Assigned  
Attorney Docket Number AN 2004.00

RECEIVED

## **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T
01	1	ACHEN, M.G. and STACKER, S.A. "The Vascular Endothelial Growth Factor Family; Proteins Which Guide the Development of the Vasculature" <i>Int. J. Exp. Path.</i> (1998) 79:255-265	
	2	AUGUSTIN, H.G. et al. "Ovarian Angiogenesis Phenotypic Characterization of Endothelial Cells in a Physiological Model of Blood Vessel Growth and Regression" <i>Am. J. Pathol.</i> (1995) 147(2):339-351	
	3	BITTER, T. and MUIR, H.M. "A Modified Uronic Acid Carbazole Reaction" <i>Anal. Chem.</i> (1962) 4:330-334	
	4	BRADFORD, M.M. "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding" <i>Anal. Biochem.</i> (1976) 72:248-254	
	5	BROOKS, P.C. et al. "Requirement of Vascular Integrin $\alpha_v\beta_3$ for Angiogenesis" <i>Science</i> (1994) 264:569-571	
	6	BROOKS, P.C. et al. "Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin $\alpha_v\beta_3$ " <i>Cell</i> (May, 1996) 85:683-693	
	7	BUSSOLINO, F., et al. "Molecular Mechanisms of Blood Vessel Formation" <i>Trends in Biochem Sci</i> (1997) 22(7):251-256	
	8	CONNOLLY, D.T. et al. "Determination of the Number of Endothelial Cells in Culture Using an Acid Phosphatase Assay" <i>Anal. Biochem.</i> (1986) 152:136-140	
	9	DEVALARAJA, M. and RICHMOND, A. "Multiple Chemotactic Factors: Fine Control or Redundancy?" <i>Trends in Pharmacol. Sci.</i> (1999) 20(4):151-156	
	10	DUBOIS, M. et al. "Colorimetric Method for Determination of Sugars and Related Substances" <i>Analyt. Chem.</i> (1956) 28:350-356	
	11	FOLKMAN, J. "Angiogenesis in Cancer, Vasular, Rheumatoid and Other Diseases" <i>Nature Med.</i> (1995) 1(1):27-31	
	12	FOLKMAN, J. and D'AMORE, P.A. "Blood Vessel Formation: What is its Molecular Basis?" <i>Cell</i> (1996) 87:1153-1155	
	13	GOODGER, A.M. (MacPherson) and ROGERS, P.A.W. "Blood Vessel Growth in the Endometrium" <i>Microcirculation</i> (1995) 2(4):329-343	
	14	HANAHAN, D. "Signaling Vascular Morphogenesis and Maintenance" <i>Science</i> (1997) 277:48-50	
	15	HEALY, D.L. et al. "Angiogenesis: A New Theory for Endometriosis" <i>Hum. Reprod. Update</i> (1998) 4(5):736-740	
	16	KOCH, A.E. et al. "Angiogenesis Mediated by Soluble Forms of E-Selectin and Vascular Cell Adhesion Molecule-1" <i>Nature</i> (1995) 376:517-519	
	17	MAISONPIERRE, P.C. et al. "Angiopoietin-2, a Natural Antagonist for Tie2 that Disrupts in vivo Angiogenesis" <i>Science</i> (1997) 277:55-60	
	18	MIGNATTI, P. and RIFKIN, D.B. "Plasminogen Activators and Matrix Metalloproteinases in Angiogenesis" <i>Enzyme Protein</i> (1996) 49:117-137	
	19	NGUYEN, M. et al. "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane" <i>Microvas. Res.</i> (1994) 47:31-40	
	20	O'REILLY, M.S. et al. "Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma" <i>Cell</i> (1994) 79(2):315-328	
	21	O'REILLY, M.S. et al. "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth" <i>Cell</i> (1997) 88(2):277-285	



## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner's  
Signature

Date  
Considered

6/24/04

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231



RECEIVED

Approved for use through 10/31/2000 OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 (44 USC 3501-3509), you are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 10/021,902,900  
Filing Date December 13, 2001  
First Named Inventor Kin-Ping WONG  
Art Unit 1651  
Examiner Name Lilling, Herbert J.  
Attorney Docket Number AN 2004.00

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
5/	1	US-4,177,108	12-4-79	Sakakida, et. al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

Examiner's  
Signature

Herbert J. Lilling

Date  
Considered

6/24/02

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.